Daniel R. Chard - 24 Feb 2023 Form 4 Insider Report for MEDIFAST INC (MED)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MED	Common Stock	Award	$0	+34,076	+241%	$0.000000	48,194	24 Feb 2023	Direct	F1
transaction	MED	Common Stock	Tax liability	$1,720,574	-15,643	-32%	$109.99	32,551	24 Feb 2023	Direct	F1
transaction	MED	Common Stock	Tax liability	$141,857	-1,358	-4.2%	$104.46	31,193	16 Mar 2023	Direct
transaction	MED	Common Stock	Tax liability	$89,598	-872	-2.8%	$102.75	30,321	17 Mar 2023	Direct
transaction	MED	Common Stock	Award	$0	+16,807	+55%	$0.000000	47,128	17 Mar 2023	Direct	F2
holding	MED	Common Stock						108,598	24 Feb 2023	The Dan and Allyson Family Irrevocable Trust	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	17,038 Performance Stock Units were granted on February 19, 2020, and vested on December 31, 2022 and converted into common stock on a two-for-one basis due to the achievement of certain performance factors. The Compensation Committee of the Medifast Board of Directors approved the performance factors on February 24, 2023 and the shares were released on March 7, 2023.
F2	Represents a grant of restricted stock units issued to the reporting person under the 2012 Share Incentive Plan that will vest in three equal annual installments beginning on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3	These shares are directly owned by The Dan and Allyson Family Irrevocable Trust, for which the reporting person is the Settlor of the Trust and Investment Trustee.